I am the principal investigator of the LEAP study. This is a multicenter, randomized delayed start study that investigates whether early treatment of Parkinson’s disease with levodopa has a delayed beneficial effect in addition to the direct symptomatic effect (

I am a co-investigator of the CHEVAL study. This is a randomized, double blind, placebo-controlled, multi-center trial that investigate whether early treatment with cholinesterase inhibitors delays the progression of minor visual hallucinations to major hallucinations without insight or dementia (

About half of the patients with Parkinson’s disease complain of orthostatic intolerance with a major impact on functioning in daily life. Although some underlying mechanisms for orthostatic hypotension are known, essential insights for the diagnosis and treatment in Parkinson’s disease are lacking — e.g. prevalence and association with orthostatic intolerance. We are studying the occurrence and characteristics of orthostatic hypotension in an incident cohort of patients with Parkinson’s disease.

In collaboration with neuropsychologists Prof. B.A. Schmand and G.J. Geurtsen, we investigate cognition in Parkinson's disease. Notable projects include (1) the assessment of cognitive impairment in the course of the disease and (2) an international collaborative Parkinson's disease-MCI validation study. Concerning the latter project, the Study Group is endorsed by the International Parkinson and Movement Disorder Society. The AMC group directs the research.
Effective start/end date01/04/2015 → …

ID: 172768